TCRX (TScan Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

TCRX (TScan Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

TCRXTScan Therapeutics, Inc.

Mkt Cap$69M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$8M

Net Income (TTM)-$130M

EPS (TTM)-$1.00

Free Cash Flow (TTM)-$140M

Gross Margin90.1%

Op. Margin-1750.6%

Net Margin-1672.7%

FCF Margin-1801.1%

P/S Ratio (TTM)8.9x

P/E Ratio (TTM)—

YoY Rev Growth+175.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$7M	$7M	-$23M
Q2 23	$3M	$3M	-$25M
Q3 23	$4M	$4M	-$25M
Q4 23	$7M	$6M	-$21M
Q1 24	$566K	$566K	-$31M
Q2 24	$536K	$536K	-$34M
Q3 24	$1M	$1M	-$33M
Q4 24	$665K	$665K	-$37M
Q1 25	$2M	$2M	-$36M
Q2 25	$3M	$3M	-$39M
Q3 25	$3M	$2M	-$37M
Q4 25	$0	$0	-$24M

Valuation

Quarter	P/S	P/E
Q1 23	4.0x	—
Q2 23	4.2x	—
Q3 23	4.1x	—
Q4 23	3.3x	—
Q1 24	4.7x	—
Q2 24	5.7x	—
Q3 24	7.4x	—
Q4 24	24.5x	—
Q1 25	15.6x	—
Q2 25	9.9x	—
Q3 25	8.2x	—
Q4 25	8.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$24M	-$24M
Q2 23	-$22M	-$22M
Q3 23	$8M	$7M
Q4 23	-$24M	-$24M
Q1 24	-$29M	-$30M
Q2 24	-$26M	-$27M
Q3 24	-$28M	-$29M
Q4 24	-$27M	-$28M
Q1 25	-$38M	-$39M
Q2 25	-$33M	-$35M
Q3 25	-$32M	-$34M
Q4 25	-$32M	-$32M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$838K
Q2 23	$420K
Q3 23	$1M
Q4 23	$469K
Q1 24	$705K
Q2 24	$862K
Q3 24	$1M
Q4 24	$888K
Q1 25	$2M
Q2 25	$1M
Q3 25	$1M
Q4 25	$171K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+125.2%	+54.0%
Q2 23	-22.4%	+43.8%
Q3 23	+15.6%	+43.6%
Q4 23	+133.0%	+31.4%
Q1 24	-91.7%	+8.1%
Q2 24	-83.0%	+24.8%
Q3 24	-73.0%	+17.6%
Q4 24	-90.8%	+30.8%
Q1 25	+283.6%	+20.3%
Q2 25	+473.9%	+20.4%
Q3 25	+139.4%	+17.5%
Q4 25	-100.0%	-36.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$1M	16.9%
Q2 23	$1M	38.8%
Q3 23	$1M	34.5%
Q4 23	$2M	20.8%
Q1 24	$2M	350.5%
Q2 24	$2M	434.3%
Q3 24	$3M	240.5%
Q4 24	$3M	408.1%
Q1 25	$3M	157.3%
Q2 25	$3M	106.4%
Q3 25	$3M	119.9%
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$22M	$8M	—
Q2 23	$21M	$7M	—
Q3 23	$23M	$6M	—
Q4 23	$22M	$6M	—
Q1 24	$25M	$7M	—
Q2 24	$27M	$8M	—
Q3 24	$26M	$7M	—
Q4 24	$29M	$7M	—
Q1 25	$30M	$8M	—
Q2 25	$33M	$9M	—
Q3 25	$31M	—	$8M
Q4 25	$20M	$6M	—

Revenue Segments

Quarter	Reportable Segment
Q1 25	$2M
Q2 25	$3M
Q3 25	$3M
Q4 25	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$96M	$0	$96M
Q2 23	$209M	$0	$209M
Q3 23	$155M	$60M	$215M
Q4 23	$133M	$59M	$192M
Q1 24	$141M	$22M	$163M
Q2 24	$242M	$56M	$298M
Q3 24	$133M	$138M	$271M
Q4 24	$179M	$111M	$290M
Q1 25	$154M	$98M	$252M
Q2 25	$169M	$49M	$218M
Q3 25	$170M	$15M	$184M
Q4 25	$152M	$0	$152M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	24M	+0.6%
Q2 23	47M	+94.9%
Q3 23	95M	+100.9%
Q4 23	95M	+0.0%
Q1 24	95M	+0.0%
Q2 24	113M	+19.6%
Q3 24	119M	+4.7%
Q4 24	121M	+1.8%
Q1 25	130M	+7.4%
Q2 25	130M	+0.0%
Q3 25	130M	+0.1%
Q4 25	130M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$98K	104
FY 22	$99K	137
FY 23	$137K	154
FY 24	$15K	194
FY 25	$0	200K